Hypothesis: Intermittent AMPK activation primes resistant senescent cells for elimination by dasatinib+quercetin (D+Q), thereby raising clearance beyond the 30‑70% ceiling observed with D+Q alone.

Resistant senescent cells survive initial D+Q exposure because they rewire mTOR‑autophagy signaling, maintaining mTORC1 activity while dampening autophagic flux [9]. This state creates a metabolic dependency on mTORC1‑driven glycolysis and a reduced capacity to cope with oxidative stress. Acute AMPK activation (e.g., with metformin or AICAR) phosphorylates TSC2 and Raptor, suppressing mTORC1, and directly activates ULK1 to initiate autophagy [6][7]. In senescent cells, this dual hit collapses the buffered glycolytic ATP supply and unleashes uncontrolled autophagic degradation, pushing the cells past a death threshold that D+Q can then exploit via its SRC/ABL inhibition and ROS generation [1].

We propose a cycling regimen: three days of AMPK activator administration followed by a single oral dose of D+Q, repeated every two weeks. The AMPK‑on phase sensitizes the resistant pool; the D+Q‑on phase executes clearance. Recovery periods allow normal tissue mTORC2 signaling to rebound, avoiding the insulin resistance and immune deficits seen with chronic mTOR inhibition [6].

Predictions: In aged mice, this AMPK‑D+Q cycle will reduce p16Ink4a‑positive cells by >90% in liver, lung and adipose tissue compared with ~50% reduction after D+Q alone (measured by flow cytometry and immunofluorescence). Concomitantly, SASP cytokines (IL‑6, IL‑1β) will drop to baseline levels, grip strength and treadmill endurance will improve by at least 30%, and median lifespan will extend by 15% over controls. If the combination fails to surpass the D+Q monotherapy clearance or does not improve functional outcomes, the hypothesis is falsified.

The approach is directly testable in ongoing human trials: adding a short course of metformin (or another AMPK activator) before each intermittent D+Q dose in patients with high senescent burden (selected via PET‑based senescence imaging) could be added as an adaptive arm to the MS and osteoporosis studies [3][4]. Safety monitoring would focus on hypoglycemia and lactic acidosis, known metformin risks, while pharmacokinetic sampling would confirm transient AMPK activation without sustained mTORC2 suppression.